Concepedia

Alexis Paquin

AP

4

Publications

50

Citations

4

H-Index

2021

Active since

Affiliations

Université du Québec à Montréal(Current)

University of Toronto

Ontario Institute for Cancer Research

Université de Montpellier

Centre National de la Recherche Scientifique

Alexis Paquin is an author at Université du Québec à Montréal specializing in drug discovery, biomolecular engineering, and molecular biology.

ORCID

Top concepts

Publications per year

2021–2024

4

Publications

4

Transcriptional regulation of CYR61 and CTGF by LM98: a synthetic YAP-TEAD inhibitor that targets in-vitro vasculogenic mimicry in glioblastoma cells

Marie-Ève Roy, Carolane Veilleux, Alexis Paquin et al. · Anti-Cancer Drugs · 2024 · 15 citations · Full text

Development of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration

Ahmed Fnaiche, Hwai‐Chien Chan, Alexis Paquin et al. · ACS Medicinal Chemistry Letters · 2023 · 13 citations · Full text

Innovative C-symmetric testosterone and androstenedione dimers: Design, synthesis, biological evaluation on prostate cancer cell lines and binding study to recombinant CYP3A4

Alexis Paquin, Yassine Oufqir, Irina F. Sevrioukova et al. · European Journal of Medicinal Chemistry · 2021 · 12 citations · Full text

, , +7

Development of LM-41 and AF-2112, two flufenamic acid-derived TEAD inhibitors obtained through the replacement of the trifluoromethyl group by aryl rings

Ahmed Fnaiche, Léa Mélin, Narjara González Suárez et al. · Bioorganic & Medicinal Chemistry Letters · 2023 · 10 citations

Rows per page

1–4 of 4